<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>High-dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, without stem cell rescue, has been used successfully to treat <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> and other <z:hpo ids='HP_0002960'>autoimmune disorders</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>To determine the safety and efficacy of high-dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> among patients with severe refractory <z:hpo ids='HP_0001890'>autoimmune hemolytic anemia</z:hpo>, we treated 9 patients with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (50 mg </plain></SENT>
<SENT sid="2" pm="."><plain>kg(-1) </plain></SENT>
<SENT sid="3" pm="."><plain>d(-1) for 4 days) who had failed a median of 3 (range, 1-7) other treatments </plain></SENT>
<SENT sid="4" pm="."><plain>The median <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> before treatment was 6.7 g/dL (range, 5-10 g/dL) </plain></SENT>
<SENT sid="5" pm="."><plain>The median time to reach an absolute neutrophil count of 500/microL or greater was 16 days (range, 12-18 days) </plain></SENT>
<SENT sid="6" pm="."><plain>Six patients achieved complete remission (<z:mpath ids='MPATH_458'>normal</z:mpath> untransfused <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> for age and sex), and none have relapsed after a median follow-up of 15 months (range, 4-29 months) </plain></SENT>
<SENT sid="7" pm="."><plain>Three patients achieved and continue in partial remission (<z:chebi fb="0" ids="35143">hemoglobin</z:chebi> at least 10 g/dL without transfusion support) </plain></SENT>
<SENT sid="8" pm="."><plain>High-dose <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> was well tolerated and induced durable remissions in patients with severe refractory <z:hpo ids='HP_0001890'>autoimmune hemolytic anemia</z:hpo> </plain></SENT>
</text></document>